Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial

Trial Profile

Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms VOLTAIRE-PSO
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 15 Nov 2023 Results of pooled subgroup analysis from five phase 3 randomized controlled clinical trials (VOLTAIRE-RA , VOLTAIRE-RAext, VOLTAIRE-CD, VOLTAIRE-PsO and VOLTAIRE-X) assessing incidence of safety endpoints in patients with RA )presented at the ACR Convergence 2023
    • 03 Jun 2023 Results of sub group analysis (from studies VOLTAIRE-RA, VOLTAIRE-CD and VOLTAIRE-PsO) comparing immunogenicity across these indications and by patient sex presented at the 24th Annual Congress of the European League Against Rheumatism
    • 14 Nov 2022 Results of immunogenicity analysis across various indications and by patient sex from VOLTAIRE trials (VOLTAIRE PSO, VOLTAIRE RA and VOLTAIRE CD) presented at the ACR Convergence 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top